Medpace Hldgs — Income Statement, Cash Flows & Balance Sheet

Is Medpace profitable?

Medpace has delivered three consecutive years of strong and accelerating profit growth.

Revenue jumped by a fifth in a single year, and operating profit kept pace almost exactly, meaning the business is holding its margins steady even as it scales rapidly. Net income grew a bit more slowly than operating income because a large foreign currency loss and a higher tax rate weighed on the bottom line in 2025 — these items distort the comparison slightly but do not reflect any weakness in the core business.

Reimbursed out-of-pocket costs make the headline revenue figure look bigger than the underlying service business.

Reimbursed out-of-pocket expenses — things like investigator site payments and travel that Medpace pays on behalf of clients and then bills back at cost — surged and now represent over 40% of total revenue. These pass-through costs carry no margin, so investors often focus on direct service costs and SG&A to judge the true operating efficiency of the business.

Where does Medpace's revenue come from?

Metabolic disease was the standout growth driver in 2025, nearly doubling in two years.

Metabolic — likely driven by the GLP-1 and obesity drug boom — overtook oncology as the largest contributor and alone accounted for roughly half of the company's total revenue growth last year. Meanwhile, the AVAI category contracted, showing that the mix of therapeutic areas is shifting meaningfully. Oncology and CNS also grew solidly, giving Medpace a broad base of demand.

Does Medpace generate cash?

Medpace converts its profits into cash at an impressive rate, and free cash flow (operating cash minus capital spending) is substantial.

Operating cash flow comfortably exceeds net income, aided by clients paying Medpace in advance before services are performed (these prepayments, called "advanced billings," added $144M to cash this year). Capital spending is modest and actually declined, making this a capital-light business that converts growth into cash efficiently.

The company deployed most of its cash hoard into a very large share buyback in 2025.

After building a cash cushion over prior years, Medpace spent nearly $920M buying back its own shares in 2025 — roughly six times more than the prior year. This explains why cash on the balance sheet fell despite record operating cash flow.

How strong is Medpace's balance sheet?

Medpace carries no debt and remains profitable, but the buyback has consumed nearly all of the equity cushion.

There is no financial debt whatsoever — the credit facility exists but has a zero balance. The large accumulated deficit is an accounting result of retiring repurchased shares at prices well above their par value, not a sign of operating losses. The company remains solidly profitable and cash-generative.

Clients pay Medpace upfront, which boosts cash but also creates a large liability on the balance sheet.

The growing gap between what clients have pre-paid and what Medpace has billed for work completed is a sign of healthy commercial momentum — customers are committing funds for future work. Remaining performance obligations (contracted but not yet earned revenue) stood at approximately $3.6 billion at year-end, providing strong near-term revenue visibility.